



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

01 Feb 2016 (#3)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- Notice of Correction to Salary Limitation on NIH Grants, and Cooperative Agreements ([NOT-OD-16-059](#))
- Reminder: NIH Natural Disaster Policy -- Winter Storm Jonas ([NOT-OD-16-061](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Prescription Drug Abuse (R01) ([NOT-DA-16-011](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) ([NOT-DA-16-012](#))
- Notice of NIH/FDA Informational Webinar - Common Misunderstandings of the Investigational Device Exemption Process for Invasive Neuromodulation Devices ([NOT-NS-16-006](#))

1. The Neural Mechanisms of Integrated Emotional and Social Representation

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** ([RFA-MH-17-300](#)) **Type:** R01

Application Due Date: June 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages grant applications that incorporate a multi-dimensional perspective into studies of the neural mechanisms underlying emotional and/or social representations. The ability to integrate a broad array of emotional and social cues is impaired in many mental disorders, yet the neural mechanisms underlying these processes are not well understood. This FOA encourages investigators to take on the challenge of investigating how diverse multi-dimensional emotional and/or social cues are represented across integrated and temporally dynamic brain circuits. This FOA solicits applications that incorporate innovative approaches designed to move affective and social neuroscience beyond single region-based, modular, and/or static models of brain function and behavior.

Budget: NIMH intends to commit \$3 million in FY2017 to support 8 awards across this FOA and its companion. Future year amounts will depend on annual appropriations. Application budgets are limited \$500,000 direct costs, annually. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. The Neural Mechanisms of Multi-Dimensional Emotional and Social Representation

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** ([RFA-MH-17-305](#)) **Type:** R21

Application Due Date: June 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages grant applications that incorporate a multi-dimensional perspective into studies of the neural mechanisms underlying emotional and/or social representations. The ability to integrate a broad array of emotional and social cues is impaired in many mental disorders, yet the neural mechanisms underlying these processes are not well understood. This FOA encourages investigators to take on the challenge of investigating how diverse multi-dimensional emotional and/or social cues are represented across integrated and temporally dynamic brain circuits. This FOA solicits applications that incorporate innovative approaches designed to move affective and social neuroscience beyond single region-based, modular, and/or static models of brain function and behavior.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Applicants may request direct costs in \$25,000 modules, up to the total direct costs limitation of \$275,000 for the combined two-year award period. The total project period may not exceed 2 years.

3. Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases

Letter of Intent due date: Usually 30 days prior to the application due date **Hyperlink:** ([PA-16-087](#)) **Type:** R21
([PA-16-088](#)) R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, aging, and mitochondrial disease

transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte, and to develop therapeutic or alternative approaches to treat mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. It is anticipated that the results from studies supported by this FOA will provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. This funding opportunity announcement encourages innovative and high-risk/impact studies that may lead to breakthrough in mitochondrial function, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in understanding and treatment of mitochondrial dysfunction.

Budget: R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum period is 2 years. **RO1** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

4. Imaging and Biomarkers for Early Cancer Detection

Letter of Intent due date: Usually 30 days prior to the application due date

Hyperlink: [\(PAR-16-089\)](#)

Type: UO1

Application Due Date: July 11, 2016; December 14, 2016; July 10, 2017; December 11, 2017; July 10, 2018; December 11, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to: (i) invite researchers to submit collaborative research project (UO1) applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach, and (ii) establish a Consortium for Imaging and Biomarkers (CIB) to perform collaborative studies, exchange information, share knowledge and leverage common resources. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. All Units are expected to participate in collaborative activities with other Units within the Consortium.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 - NIH Director's Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director's Pioneer Award is not renewable.

DP3 - Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 - Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 - NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 - NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 - NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 - NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 - NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 - Resource-Related Research Projects - Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 - NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 - NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R - International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on "PA" to search for further funding opportunities*)

RFA Request for Applications (*click on "RFA" to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)